🇺🇸 FDA
Patent

US 10047122

Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use

granted A61KA61K38/005

Quick answer

US patent 10047122 (Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K38/005